Atorvastatin calcium: CONCLUSIONS(2)
Comparative data from multicentre, randomized, clinical trials demonstrate that, at a starting dose of 10 mg/day, ator-vastatin produces greater reductions in LDL-C levels (and total cholesterol levels) than those observed with the starting doses of other HMG-CoA reductase inhibitors. Higher doses of atorvastatin are more effective than equivalent doses of other HMG-CoA reductase inhibitors and offer the option of greater reductions in lipoprotein levels in patients requiring this. More patients reach treatment goals with atorvastatin than with other HMG-CoA reductase inhibitors. The efficacy of atorvastatin is similar between men and women and between young and elderly patients.
Clinical data also demonstrate the effectiveness of atorvastatin in a broad range of patients with dyslipidemia, including hypercholesterolemia, mixed dyslipidemia, hypertriglyceridemia, familial forms of hypercholesterolemia and in dyslipidemia associated with type II diabetes. Analysis of data by dyslipidemic type from clinical trials has indicated that atorvastatin appears to lower preferentially the lipoprotein particles that are most elevated within each dyslipidemic state, rather than target only one lipoprotein fraction.